{"id":35166,"date":"2025-06-13T14:42:19","date_gmt":"2025-06-13T06:42:19","guid":{"rendered":"https:\/\/flcube.com\/?p=35166"},"modified":"2025-06-13T14:50:17","modified_gmt":"2025-06-13T06:50:17","slug":"transthera-sciences-sets-hong-kong-ipo-at-hkd13-15-per-share","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35166","title":{"rendered":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share"},"content":{"rendered":"\n<p>China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>TransThera Sciences, a clinical-stage biopharmaceutical company, focuses on developing innovative small molecule therapies for oncology, inflammation, and cardiometabolic diseases. The company has a pipeline of six clinical-stage candidates and one preclinical asset.<\/p>\n\n\n\n<p><strong>Pipeline Highlights<\/strong><br>The company&#8217;s flagship product, tinengotinib, is a multiple tyrosine kinase (MTK) inhibitor targeting FGFR\/VEGFR, JAK, and Aurora. It is currently undergoing pivotal\/regulatory studies in previously treated cholangiocarcinoma (CCA). Tinengotinib is also being investigated for metastatic castration-resistant prostate cancer (mCRPC), breast cancer, biliary tract cancers (BTC), and pan-FGFR solid tumors. Phase II studies have been completed, and the company plans to evaluate its potential in combination with cadonilimab or ivonescimab for hepatocellular carcinoma (HCC) in Phase II trials.<\/p>\n\n\n\n<p><strong>IPO Details<\/strong><br>The IPO has secured five cornerstone investors, including Akeso Biopharma, with total commitments of approximately HKD 130 million (USD 17 million). The net proceeds from the offering are estimated at HKD 161 million (USD 21 million). Ten percent of the proceeds (HKD 16.1 million) will be allocated to general working capital, while 90% (HKD 145 million) will fund the ongoing global Phase III trial of tinengotinib as a monotherapy for CCA.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025061300036_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025061300036_c.\"><\/object><a id=\"wp-block-file--media-e5ba54e7-c289-47c3-a6c7-33955dda77de\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025061300036_c.pdf\">2025061300036_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025061300036_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e5ba54e7-c289-47c3-a6c7-33955dda77de\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,72,601],"class_list":["post-35166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-ipo","tag-transthera-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share\" \/>\n<meta property=\"og:description\" content=\"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35166\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-13T06:42:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-13T06:50:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share\",\"datePublished\":\"2025-06-13T06:42:19+00:00\",\"dateModified\":\"2025-06-13T06:50:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1301-1.webp\",\"keywords\":[\"Cancer\",\"IPO\",\"TransThera Sciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35166#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35166\",\"name\":\"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1301-1.webp\",\"datePublished\":\"2025-06-13T06:42:19+00:00\",\"dateModified\":\"2025-06-13T06:50:17+00:00\",\"description\":\"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35166\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1301-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1301-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share - Insight, China&#039;s Pharmaceutical Industry","description":"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35166","og_locale":"en_US","og_type":"article","og_title":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share","og_description":"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.","og_url":"https:\/\/flcube.com\/?p=35166","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-13T06:42:19+00:00","article_modified_time":"2025-06-13T06:50:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35166#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35166"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share","datePublished":"2025-06-13T06:42:19+00:00","dateModified":"2025-06-13T06:50:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35166"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35166#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","keywords":["Cancer","IPO","TransThera Sciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35166#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35166","url":"https:\/\/flcube.com\/?p=35166","name":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35166#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35166#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","datePublished":"2025-06-13T06:42:19+00:00","dateModified":"2025-06-13T06:50:17+00:00","description":"China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35166"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35166#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","width":1080,"height":608,"caption":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1301-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35166"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35166\/revisions"}],"predecessor-version":[{"id":35172,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35166\/revisions\/35172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35167"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}